Business Context and Reporting Period
This Form 8-K Current Report, dated September 2, 2025, pertains to Perspective Therapeutics, Inc. (NYSE American: CATX), a biopharmaceutical company based in Seattle, Washington. The filing primarily addresses a significant leadership transition within the company's executive management team.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Mr. Joel Sendek as Chief Financial Officer (CFO) and principal financial officer, effective September 4, 2025. Concurrently, Mr. Juan Graham ceased serving as CFO on the same date.
- New CFO: Joel Sendek, age 58, brings over 30 years of life sciences experience, including previous CFO roles at Spero Therapeutics, Dewpoint Therapeutics, Sema4, and Forward Pharma A/S, as well as senior research roles at Oppenheimer & Co., Stifel Financial Corp., and Lazard.
- Departing CFO: Juan Graham's departure is subject to a separation agreement and release of claims, with severance terms defined in his prior employment agreement filed in the 2025 Form 10-K.
Compensation, Outlook, and Risks
The filing details the compensatory arrangements for the new CFO under a newly executed Employment Agreement:
- Base Salary: $500,000 annually.
- Annual Bonus: Target opportunity of 40% of base salary, pro-rated for 2025.
- Equity Grant: One-time grant of options to purchase 600,000 shares of common stock. Vesting is 25% on the first anniversary of the effective date, followed by 36 equal monthly increments. The exercise price is the closing price on the grant date.
- Severance Provisions:
- Standard Termination (Without Cause/Good Reason): 12 months of salary, pro-rated target bonus, and 12 months of COBRA premiums.
- Change in Control (CIC) Termination: 12 months of salary, pro-rated target bonus, an additional target bonus amount, 12 months of COBRA, and accelerated vesting of equity awards (time-based fully vested; performance-based vested at target levels).
Risks and Contingencies: The filing notes standard confidentiality restrictions and a one-year non-solicitation covenant for customers and employees. The full text of the Employment Agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Investor Verification Checklist
- Verify the exact grant date and exercise price for Mr. Sendek's 600,000 stock options once the Grant Date is finalized.
- Review the separation agreement terms for Mr. Juan Graham to confirm the specific severance payout amount.
- Monitor the upcoming Form 10-Q for the quarter ending September 30, 2025, for the full text of the Employment Agreement and any updated financial guidance.
- Assess the impact of the leadership change on the company's strategic direction and capital allocation plans in future investor communications.